AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
As approved by the companyâs shareholders on 14 November 2018 and the Supreme Court of Victoria (Court) on 16 November 2018 the scheme of arrangement between Zenitas and its shareholders has been implemented. Guardian Alphabet Pty Ltdâs wholly owned subsidiary Zenitas has resulted in which in turn is controlled by funds managed or advised by Liverpool Partners Guardian GP Pty Ltd. and funds managed or advised by Adamantem Capital Management Pty Ltd.
The companyâs shareholders have been paid $1.445 cash per Zenitas share as consideration for the transfer of Zenitas shares to BidCo who held shares on the record date of 5.00pm on Friday 7 December 2018. ZNT has paid to each option holder an amount equal to $1.445 less the exercise price of the ZNT option as consideration for the cancellation of all existing ZNT options on the issue as at close of trading on 13 December 2018 on ASX.
About the remaining 49% of NexttCare Pty Ltd, funded from the companyâs existing debt facilities for the remaining 49% of NexttCare, the company has advised the settlement of the acquisition and the acquisition price was $14.7M plus transaction costs. As instructed by the company under Listing Rule 17.11, the company will be removed from the Official List of ASX Limited from the close of trading on Thursday, 13 December 2018. In connection with the acquisition of all the issued capital in ZNT by Guardian Alphabet Pty Ltd. following implementation of the scheme of arrangement between ZNT and its shareholders.
The stock of Zenitas Healthcare Limited (ASX:ZNT) is currently under the suspended status and last traded at a market price of $1.440 under the health care sector. The company has a performance change of 19.50% over the past 12 months and 37.80% in the last six months. The number of shares issued was at 74.4 million.
Disclaimer
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
